Search

Displaying results 5321 - 5330 of 9333 in total
  1. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. … XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.

  2. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. … FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC).

  3. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant.

  4. Drug

    Galegenimab

    go.drugbank.com/drugs/DB18860
    Investigational

    Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to

  5. Drug

    Mongersen

    go.drugbank.com/drugs/DB15019
    Investigational

    Mongersen is under investigation in clinical trial NCT02957474 (A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects

  6. Drug

    Tuspetinib

    go.drugbank.com/drugs/DB15343
    Investigational

    Tuspetinib (HM-43239) is under investigation in clinical trial NCT03850574 (Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed

  7. Drug

    MK-2748

    go.drugbank.com/drugs/DB15371
    Investigational

    MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).

  8. Drug

    Tilmanocept

    go.drugbank.com/drugs/DB15373
    ApprovedInvestigationalWithdrawn

    Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed

  9. Drug

    Iboctadekin

    go.drugbank.com/drugs/DB14920
    Investigational

    Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).

  10. Drug

    Vixarelimab

    go.drugbank.com/drugs/DB16350
    Investigational

    Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis).